Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan

Breast Cancer

Volumn 17, Issue 3, 2010, Pages 190-198

  Kimura, Morihiko ^a,l   Tominaga, Takeshi ^b   Takatsuka, Yuichi ^c   Toi, Masakazu ^d   Abe, Rikiya ^e   Koyama, Hiroki ^f   Takashima, Shigemitsu ^g   Nomura, Yasuo ^h   Miura, Shigeto ⁱ   Kimijima, Izo ⁱ   Tashiro, Hideya ^j   Ohashi, Yasuo ^k  

^a GUNMA PREFECTURAL CANCER CENTER   (Japan)

^b SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j MATSUYAMA RED CROSS HOSPITAL   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l General Ota Hospital   (Japan)

more..

Author keywords

Adjuvant; Breast cancer; CEF; Chemotherapy; CMF; Post operative

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPAN; LEUKOCYTE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SKIN METASTASIS; THROMBOCYTE COUNT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; VOMITING; ADENOCARCINOMA; ADENOCARCINOMA, SCIRRHOUS; ADJUVANT CHEMOTHERAPY; AXILLA; BREAST NEOPLASMS; CARCINOMA, PAPILLARY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADENOCARCINOMA; ADENOCARCINOMA, SCIRRHOUS; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA, PAPILLARY; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; JAPAN; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; RECEPTORS, ESTROGEN; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955516238     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0132-x     Document Type: Article

References (21)

1. G Bonadonna E Brusamolino P Valagusa 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405 410 1:STN:280:DyaE287gtVKrtA%3D%3D 1246307
2. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 death among 75,000 women Lancet 339 1 15
3. Y Nomura T Tominaga I Adachi H Koyama A Fukami 1994 Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan Gan To Kagaku Ryoho 21 12 1949 1956 1:STN:280:DyaK2czmvVWhtw%3D%3D 8085846
4. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 9114 1451 1467 10.1016/S0140-6736(97)11423-4 (Pubitemid 28227036)
5. P Eifel JA Axelson J Costa J Crowley WJ Curran Jr A Deshler, et al. 2001 National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000 J Natl Cancer Inst 93 13 979 989 10.1093/jnci/93.13.979 1:STN:280:DC%2BD3MzpvFamtA%3D%3D 11438563
6. HT Mouridsen 1993 Adjuvant systemic therapy in breast cancer Eur J Cancer 29A 4 595 598 10.1016/S0959-8049(05)80160-1 1:STN:280:DyaK3s7mvVCmuw%3D%3D 8435216
7. GN Hortobagyi AU Buzdar 1993 Present status of anthracyclines in the adjuvant treatment of breast cancer Drugs 45 Suppl 2 10 19 10.2165/00003495- 199300452-00004 7693417
8. G Bonadonna M Zambetti P Valagussa 1995 Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes JAMA 273 542 547 10.1001/jama.273.7.542 1:STN:280:DyaK2M7jvFWqtw%3D%3D 7837388
9. B Fisher C Redmond DL Wickerham D Bowman H Schipper 1989 Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience J Clin Oncol 7 572 582 1:STN:280:DyaL1M3hsF2msw%3D%3D 2651576 (Pubitemid 19126792)
10. B Fisher AM Brown NV Dimitrov R Poisson C Redmond RG Margolese D Bowman N Wolmark DL Wickerham CG Kardinal 1990 Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 1 1483 1496
11. P Fumoleau Y Devaux ML Vo Van P Kerbrat P Fargeot S Schraub J Mihura M Namer M Mercier 1993 Pre-menopausal patients with node-positive resectable breast cancer Drugs 45 Suppl 2 38 45 10.2165/00003495-199300452-00007 7693420
12. J Wils RC Coombes M Marty J Bliss E Woods 1993 Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG) Drugs 45 Suppl 2 46 50 10.2165/00003495-199300452-00008 7693422
13. MN Levine K Bramwell K Pritchard D Perrault B Findlay H Abu-Zahra D Warr A Arnold J Skillings 1993 The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer Drugs 45 Suppl 2 51 59 10.2165/00003495-199300452-00009 7693423
14. DA Schoenfeld JR Richter 1982 Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint Biometrics 38 163 170 10.2307/2530299 1:STN:280:DyaL383gs12gtg%3D%3D 7082758
15. RC Coombes JM Bliss J Wils F Morvan M Espie D Amadori P Gambrosier M Richards M Aapro A Villar-Grimalt C McArdle FR Perez-Lopez P Vassilopoulos EP Ferreira CE Chilvers G Coombes EM Woods M Marty 1996 Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group J Clin Oncol 14 35 45 1:CAS:528:DyaK28XhtVOjtrY%3D 8558217
16. B Fisher S Anderson E Tan-Chiu N Wolmark DL Wickerham ER Fisher NV Dimitrov JN Atkins N Abramson S Merajver EH Romond CG Kardinal HR Shibata RG Margolese WB Farrar 2001 Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 J Clin Oncol 19 931 942 1:CAS:528:DC%2BD3MXhvFersb0%3D 11181655 (Pubitemid 32176267)
17. J van der Hage C van de Velde J-P Julien, et al. 2001 Preoperative chemotherapy in primary breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902 J Clin Oncol 19 4224 4237 11709566
18. MN Levine VH Bramwell KI Pritchard BD Norris LE Shepherd H Abu-Zahra, et al. 1998 Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16 8 2651 2658 1:CAS:528:DyaK1cXlsFCguro%3D 9704715
19. MJ Piccart A Di Leo M Beauduin A Vindevoghel J Michel C Focan A Tagnon F Ries P Gobert C Finet MT Closon-Dejardin JP Dufrane J Kerger F Liebens S Beauvois S Bartholomeus S Dolci JP Lobelle M Paesmans JM Nogaret 2001 Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer J Clin Oncol 19 12 3103 3110 1:CAS:528:DC%2BD3MXltFektLo%3D 11408507
20. French Adjuvant Study Group 2001 Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 Randomized Trial J Clin Oncol 19 602 611
21. J Boneterre H Roche P Kerbrat, et al. 2004 Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin and cyclophosphamide with either 50 or 100 mg of epirubicin as adjuvant therapy for node-positive breast cancer J Clin Oncol 22 3070 3079 10.1200/JCO.2004.03.098 (Pubitemid 41103719)